NASDAQ:ICCC ImmuCell (ICCC) Stock Price, News & Analysis $10.62 +0.36 (+3.51%) As of 01:58 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOwnershipSEC Filings About ImmuCell Stock (NASDAQ:ICCC) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get ImmuCell alerts:Sign Up Key Stats Today's Range$10.65▼$10.6550-Day Range$9.58▼$10.7952-Week Range$4.52▼$12.10Volume329 shsAverage Volume22,558 shsMarket Capitalization$96.45 millionP/E Ratio132.77Dividend YieldN/APrice TargetN/AConsensus RatingHold Company Overview ImmuCell Corporation is a biotechnology and animal health company headquartered in Portland, Maine. The company develops, manufactures, and commercializes products designed to support the health and productivity of livestock, with a primary focus on cattle. ImmuCell’s products include FirstStep Calf Health, an on-farm diagnostic test that helps dairy and beef producers assess whether newborn calves have received adequate passive immunity from colostrum. The company also develops antibody-based products intended to help prevent or manage common diseases affecting young livestock, including neonatal calf diarrhea. Founded in 1987, ImmuCell serves the animal health market in the United States and has pursued regulatory approvals and commercial partnerships to expand the availability of its products. The company is led by President and Chief Executive Officer Michael F. Brigham.AI Generated. May Contain Errors. Read More ImmuCell Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks21st Percentile Overall ScoreICCC MarketRank™: 1.064310390645 of 5 starsImmuCell scored higher than 21% of companies evaluated by MarketBeat, and ranked 822nd out of 905 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.2 / 5Analyst RatingHold Consensus RatingImmuCell has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, no buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageImmuCell has only been the subject of 1 research reports in the past 90 days.Read more about ImmuCell's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of ImmuCell is 132.83, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 27.06.Price to Earnings Ratio vs. SectorThe P/E ratio of ImmuCell is 132.83, which means that it is trading at a more expensive P/E ratio than the Healthcare sector average P/E ratio of about 36.87.Read more about ImmuCell's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.21% of the float of ImmuCell has been sold short.Short Interest Ratio / Days to CoverImmuCell has a short interest ratio ("days to cover") of 1.35, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in ImmuCell has recently decreased by 18.13%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldImmuCell does not currently pay a dividend.Dividend GrowthImmuCell does not have a long track record of dividend growth. News and Social Media2.6 / 5News Sentiment1.16 News SentimentImmuCell has a news sentiment score of 1.16. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.69 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 2 news articles for ImmuCell this week, compared to 2 articles on an average week. Company Ownership0.4 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, ImmuCell insiders have not sold or bought any company stock.Percentage Held by Insiders5.70% of the stock of ImmuCell is held by insiders.Percentage Held by Institutions13.47% of the stock of ImmuCell is held by institutions.Read more about ImmuCell's insider trading history. Receive ICCC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ImmuCell and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ICCC Stock News HeadlinesImmuCell Q3 Preliminary Sales RiseOctober 13, 2026 | finance.yahoo.comImmuCell Reports Preliminary Q3 2026 Sales Growth Of 46%;Stock UpOctober 13, 2026 | rttnews.comNvidia's $550 Trillion ProblemDo not buy another AI stock until you've seen the arithmetic below. Nvidia is worth about $5.5 trillion. Alphabet about $4.1 trillion. Microsoft about $3.8 trillion. So what would it take to repeat Nvidia's run? A 100x gain from here puts Nvidia near $550 trillion. Nothing in history has ever been worth that. Big money in Nvidia has already been made. By the people who bought it years ago. But that does not mean the AI boom is finished. It means the opportunity has moved underneath it... to the layer every AI company has to pay to use.October 28 at 1:00 AM | Decentralized Masters (Ad)Immucell Corporation Reports Preliminary Unaudited Sales Results for the Third Quarter and Nine Months Ended September 30, 2026October 12, 2026 | marketscreener.comMImmuCell Reports Preliminary Third Quarter 2026 Sales Up 46% to $8.0 MillionOctober 12, 2026 | quiverquant.comQImmuCell Announces a 46% Increase in Product Sales in Quarter Three of 2026, Based on Preliminary, Unaudited Sales ResultsOctober 12, 2026 | globenewswire.comImmuCell Corporation (ICCC) Q2 2026 Earnings Call TranscriptAugust 14, 2026 | seekingalpha.comImmuCell Announces Unaudited Financial Results for the Quarter Ended June 30, 2026August 13, 2026 | finance.yahoo.comSee More Headlines ICCC Stock Analysis - Frequently Asked Questions How have ICCC shares performed this year? ImmuCell's stock was trading at $6.15 at the start of the year. Since then, ICCC shares have increased by 73.1% and is now trading at $10.6440. How were ImmuCell's earnings last quarter? ImmuCell Corporation (NASDAQ:ICCC) issued its quarterly earnings data on Thursday, August, 13th. The biotechnology company reported $0.20 earnings per share for the quarter, beating analysts' consensus estimates of $0.05 by $0.15. The biotechnology company earned $7.19 million during the quarter, compared to analysts' expectations of $5.40 million. Read the conference call transcript. How do I buy shares of ImmuCell? Shares of ICCC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of ImmuCell own? Based on aggregate information from My MarketBeat watchlists, some other companies that ImmuCell investors own include CRISPR Therapeutics (CRSP), MARA (MARA), Novavax (NVAX), Neurocrine Biosciences (NBIX), Aqua Metals (AQMS), Boxlight (BOXL) and Cleanspark (CLSK). Company Calendar Last Earnings8/13/2026Today10/28/2026Next Earnings (Estimated)11/12/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (9m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 ICCC's financial health is in the Green zone, according to TradeSmith. ICCC has been in this zone for over 9 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:ICCC CIK811641 Webwww.immucell.com Phone(207) 878-2770Fax207-878-2117Employees73Year Founded1982Profitability EPS (Trailing Twelve Months)$0.08 Trailing P/E Ratio132.77 Forward P/E RatioN/A P/E GrowthN/ANet Income-$1.04 million Net Margins2.57% Pretax Margin2.78% Return on Equity2.69% Return on Assets1.76% Debt Debt-to-Equity Ratio0.22 Current Ratio4.75 Quick Ratio2.71 Sales & Book Value Annual Sales$30.68 million Price / Sales3.14 Cash Flow$0.20 per share Price / Cash Flow53.17 Book Value$2.99 per share Price / Book3.55Miscellaneous Outstanding Shares9,082,000Free Float8,564,000Market Cap$96.45 million OptionableNot Optionable Beta0.56 Social Links 7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free Report This page (NASDAQ:ICCC) was last updated on 10/28/2026 by MarketBeat.com Staff. From Our PartnersFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | Sponsored80 Days Until America's Rare Earth Supply Chain ShiftChina controls more than 90% of global rare earth alloy production, leverage it is using to restrict exports t...The Tomorrow Investor | SponsoredManagement just bought 2.8 million sharesManagement just backed a $100 million buyback, repurchasing 2.8 million shares at an average price of $35.26 i...Monument Traders Alliance | SponsoredExecutive Order 14241 Unleashes Trump’s New DollarA landmark executive order, 14241, is reportedly set to reshape how Americans use money starting this December...Porter & Company | SponsoredElon Musk about to bankrupt Amazon, Microsoft & Google?Jeff Brown, the former tech executive who called the rise of Bitcoin, Tesla, and Nvidia years early, is tracki...Brownstone Research | SponsoredNvidia's $550 Trillion ProblemDo not buy another AI stock until you've seen the arithmetic below. Nvidia is worth about $5.5 trillion. Al...Decentralized Masters | SponsoredYour book is insideBlane Markham and the Markham Trading Team are giving readers a limited window to download their options strat...TradeWins | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ImmuCell Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share ImmuCell With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
